Construction of the new R&D building in Marburg, Germany, at CSL Behring’s largest production and research site is progressing rapidly.
Designed with seven floors and almost 131,000 square feet (40,000 square meters) of space, the facility will be home to CSL Behring’s R&D community. CSL Behring develops and manufactures treatments for patients with rare and serious diseases – and the additional research capacity will help the company deliver on its promise to patients.
Construction began in November 2019. A year later, five floors are in place and the finishing of the second floor was celebrated with a “ceiling party.” The new space is intended to create the best possible conditions for innovation, company leaders said. The building was designed to provide creating space for cooperation and creativity.
“Our working environment is built on a safe, diverse and inclusive culture that fosters curiosity and creativity and allows our colleagues to develop their skills and contribute to sustainable results,” said Vicky Pirzas, Vice President, Recombinant Product Development in Marburg.
About 500 R&D experts will work in state-of-the-art laboratories when the R&D campus opens in the third quarter of 2022.
